Does the media favor GLUE or ACAD?

In the previous week, ACADIA Pharmaceuticals had 2 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 5 mentions for ACADIA Pharmaceuticals and 3 mentions for Monte Rosa Therapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.69 beat Monte Rosa Therapeutics' score of 0.45 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to EWTX or GLUE?

In the previous week, Edgewise Therapeutics had 10 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 13 mentions for Edgewise Therapeutics and 3 mentions for Monte Rosa Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.52 beat Monte Rosa Therapeutics' score of 0.45 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monte Rosa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, GLUE or PBLS?

Parabilis Medicines has lower revenue, but higher earnings than Monte Rosa Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Monte Rosa Therapeutics $123.67M 8.20 -$38.63M -$1.76 N/A Parabilis Medicines N/A N/A N/A N/A N/A

Does the media prefer GLUE or PBLS?

In the previous week, Parabilis Medicines had 3 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 6 mentions for Parabilis Medicines and 3 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.45 beat Parabilis Medicines' score of 0.34 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Parabilis Medicines 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor GLUE or RLAY?

In the previous week, Monte Rosa Therapeutics and Monte Rosa Therapeutics both had 3 articles in the media. Relay Therapeutics' average media sentiment score of 0.65 beat Monte Rosa Therapeutics' score of 0.45 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relay Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GLUE or CELC?

In the previous week, Celcuity had 3 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 6 mentions for Celcuity and 3 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.45 beat Celcuity's score of 0.43 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Celcuity 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Monte Rosa Therapeutics (GLUE) Competitors

$11.89 -0.71 (-5.63%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$12.00 +0.11 (+0.92%)

As of 04:01 AM Eastern

Compare

GLUE vs. ACAD, EWTX, PBLS, RLAY, and CELC

Should you buy Monte Rosa Therapeutics stock or one of its competitors? Monte Rosa Therapeutics's main competitors and comparable companies include ACADIA Pharmaceuticals (ACAD), Edgewise Therapeutics (EWTX), Parabilis Medicines (PBLS), Relay Therapeutics (RLAY), and Celcuity (CELC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Monte Rosa Therapeutics compare to ACADIA Pharmaceuticals?

Monte Rosa Therapeutics (NASDAQ:GLUE) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Monte Rosa Therapeutics' net margin of -560.85%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

Monte Rosa Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

ACADIA Pharmaceuticals has higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	8.20	-$38.63M	-$1.76	N/A
ACADIA Pharmaceuticals	$1.07B	4.09	$391M	$2.22	11.45

In the previous week, ACADIA Pharmaceuticals had 2 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 5 mentions for ACADIA Pharmaceuticals and 3 mentions for Monte Rosa Therapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.69 beat Monte Rosa Therapeutics' score of 0.45 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Monte Rosa Therapeutics currently has a consensus price target of $28.50, indicating a potential upside of 139.70%. ACADIA Pharmaceuticals has a consensus price target of $34.36, indicating a potential upside of 35.12%. Given Monte Rosa Therapeutics' higher possible upside, analysts clearly believe Monte Rosa Therapeutics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

ACADIA Pharmaceuticals beats Monte Rosa Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Edgewise Therapeutics has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

In the previous week, Edgewise Therapeutics had 10 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 13 mentions for Edgewise Therapeutics and 3 mentions for Monte Rosa Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.52 beat Monte Rosa Therapeutics' score of 0.45 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monte Rosa Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Edgewise Therapeutics presently has a consensus price target of $51.33, indicating a potential upside of 25.05%. Monte Rosa Therapeutics has a consensus price target of $28.50, indicating a potential upside of 139.70%. Given Monte Rosa Therapeutics' higher possible upside, analysts clearly believe Monte Rosa Therapeutics is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Monte Rosa Therapeutics has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Monte Rosa Therapeutics	$123.67M	8.20	-$38.63M	-$1.76	N/A

Edgewise Therapeutics has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Edgewise Therapeutics' return on equity of -39.01% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by company insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Monte Rosa Therapeutics beats Edgewise Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Parabilis Medicines?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Parabilis Medicines has lower revenue, but higher earnings than Monte Rosa Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	8.20	-$38.63M	-$1.76	N/A
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Parabilis Medicines has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Parabilis Medicines' return on equity of 0.00% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
Parabilis Medicines	N/A	N/A	N/A

Monte Rosa Therapeutics presently has a consensus target price of $28.50, indicating a potential upside of 139.70%. Parabilis Medicines has a consensus target price of $41.67, indicating a potential upside of 25.09%. Given Monte Rosa Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Monte Rosa Therapeutics is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Parabilis Medicines had 3 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 6 mentions for Parabilis Medicines and 3 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.45 beat Parabilis Medicines' score of 0.34 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Parabilis Medicines	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Monte Rosa Therapeutics beats Parabilis Medicines on 7 of the 11 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Relay Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

In the previous week, Monte Rosa Therapeutics and Monte Rosa Therapeutics both had 3 articles in the media. Relay Therapeutics' average media sentiment score of 0.65 beat Monte Rosa Therapeutics' score of 0.45 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relay Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Monte Rosa Therapeutics currently has a consensus target price of $28.50, suggesting a potential upside of 139.70%. Relay Therapeutics has a consensus target price of $25.92, suggesting a potential upside of 43.74%. Given Monte Rosa Therapeutics' higher probable upside, equities research analysts plainly believe Monte Rosa Therapeutics is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Monte Rosa Therapeutics has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	8.20	-$38.63M	-$1.76	N/A
Relay Therapeutics	$10.35M	381.75	-$276.48M	-$1.57	N/A

Monte Rosa Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market.

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Relay Therapeutics has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Relay Therapeutics' return on equity of -42.27% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
Relay Therapeutics	N/A	-42.27%	-38.67%

Summary

Relay Therapeutics beats Monte Rosa Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Celcuity?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 63.3% of Celcuity shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 13.3% of Celcuity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Celcuity has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Monte Rosa Therapeutics' return on equity of -43.31% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
Celcuity	N/A	-350.78%	-41.54%

Monte Rosa Therapeutics currently has a consensus price target of $28.50, suggesting a potential upside of 139.70%. Celcuity has a consensus price target of $154.75, suggesting a potential upside of 93.46%. Given Monte Rosa Therapeutics' higher possible upside, research analysts clearly believe Monte Rosa Therapeutics is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Monte Rosa Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

In the previous week, Celcuity had 3 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 6 mentions for Celcuity and 3 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.45 beat Celcuity's score of 0.43 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Celcuity	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Monte Rosa Therapeutics has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	8.20	-$38.63M	-$1.76	N/A
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

Summary

Monte Rosa Therapeutics beats Celcuity on 11 of the 16 factors compared between the two stocks.

Get Monte Rosa Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLUE vs. The Competition

Export

Metric	Monte Rosa Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.07B	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-6.76	13.88	274.02	25.69
Price / Sales	8.20	1,311.41	633.28	76.04
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	3.32	15.30	10.44	6.32
Net Income	-$38.63M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-5.63%	-1.71%	-0.66%	0.17%
1 Month Performance	-13.65%	-6.17%	-3.16%	-3.27%
1 Year Performance	79.61%	30.64%	15.15%	5.58%

Monte Rosa Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLUE Monte Rosa Therapeutics	2.1338 of 5 stars	$11.89 -5.6%	$28.50 +139.7%	+87.8%	$1.07B	$123.67M	N/A	173
ACAD ACADIA Pharmaceuticals	4.3703 of 5 stars	$27.92 +0.7%	$34.36 +23.1%	+7.8%	$4.81B	$1.07B	12.58	798	Positive News Analyst Forecast
EWTX Edgewise Therapeutics	3.3918 of 5 stars	$44.08 +2.7%	$50.33 +14.2%	+172.0%	$4.79B	N/A	N/A	127	Positive News Analyst Forecast
PBLS Parabilis Medicines	3.3833 of 5 stars	$36.65 +0.9%	$41.67 +13.7%	N/A	$4.53B	N/A	N/A	145	Positive News
RLAY Relay Therapeutics	2.3771 of 5 stars	$18.86 -0.2%	$25.92 +37.4%	+305.2%	$4.14B	$15.35M	N/A	192

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GLUE) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Monte Rosa Therapeutics (GLUE) Competitors

GLUE vs. ACAD, EWTX, PBLS, RLAY, and CELC

How does Monte Rosa Therapeutics compare to ACADIA Pharmaceuticals?

Summary

How does Monte Rosa Therapeutics compare to Edgewise Therapeutics?

Summary

How does Monte Rosa Therapeutics compare to Parabilis Medicines?

Summary

How does Monte Rosa Therapeutics compare to Relay Therapeutics?

Summary

How does Monte Rosa Therapeutics compare to Celcuity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLUE vs. The Competition

Monte Rosa Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Monte Rosa Therapeutics (GLUE) Competitors

GLUE vs. ACAD, EWTX, PBLS, RLAY, and CELC

How does Monte Rosa Therapeutics compare to ACADIA Pharmaceuticals?

Is GLUE or ACAD more profitable?

Which has more volatility and risk, GLUE or ACAD?

Which has higher valuation & earnings, GLUE or ACAD?

Does the media favor GLUE or ACAD?

Do insiders & institutionals believe in GLUE or ACAD?

Do analysts recommend GLUE or ACAD?

Summary

How does Monte Rosa Therapeutics compare to Edgewise Therapeutics?

Which has more risk & volatility, EWTX or GLUE?

Does the media refer more to EWTX or GLUE?

Do analysts rate EWTX or GLUE?

Which has higher valuation & earnings, EWTX or GLUE?

Is EWTX or GLUE more profitable?

Do institutionals & insiders believe in EWTX or GLUE?

Summary

How does Monte Rosa Therapeutics compare to Parabilis Medicines?

Which has higher earnings & valuation, GLUE or PBLS?

Do institutionals and insiders believe in GLUE or PBLS?

Is GLUE or PBLS more profitable?

Do analysts recommend GLUE or PBLS?

Does the media prefer GLUE or PBLS?

Summary

How does Monte Rosa Therapeutics compare to Relay Therapeutics?

Does the media favor GLUE or RLAY?

Do analysts prefer GLUE or RLAY?

Which has higher earnings and valuation, GLUE or RLAY?

Which has more risk and volatility, GLUE or RLAY?

Do institutionals and insiders believe in GLUE or RLAY?

Is GLUE or RLAY more profitable?

Summary

How does Monte Rosa Therapeutics compare to Celcuity?

Do insiders and institutionals believe in GLUE or CELC?

Is GLUE or CELC more profitable?

Do analysts prefer GLUE or CELC?

Which has more risk & volatility, GLUE or CELC?

Does the media favor GLUE or CELC?

Which has preferable valuation and earnings, GLUE or CELC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLUE vs. The Competition

Monte Rosa Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools